Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease

Gene

Volumn 570, Issue 1, 2015, Pages 115-121

  Nagpal, Neha ^a   Goyal, Sukriti ^b   Wahi, Divya ^c   Jain, Ritu ^c   Jamal, Salma ^b   Singh, Aditi ^c   Rana, Preeti ^c   Grover, Abhinav ^c  

^a DELHI TECHNOLOGICAL UNIVERSITY   (India)

^b BANASTHALI UNIVERSITY   (India)

^c JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

Boceprevir; HCV; Molecular dynamics; Mutants; Resistance; Simulations

Indexed keywords

BOCEPREVIR; HEPACIVIRIN; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; NS3 PROTEIN, HEPATITIS C VIRUS; PROLINE; VIRUS PROTEIN;

ANTIVIRAL RESISTANCE; ARTICLE; BINDING AFFINITY; BINDING SITE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BINDING; ENZYME ACTIVITY; HEPATITIS C VIRUS; HYDROGEN BOND; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR DYNAMICS; MUTANT; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN STRUCTURE; VIRUS ENVELOPE; VIRUS MUTATION; WILD TYPE; ANALOGS AND DERIVATIVES; CHEMISTRY; ENZYME ACTIVE SITE; ENZYMOLOGY; GENETICS; HEPACIVIRUS; MISSENSE MUTATION;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; CATALYTIC DOMAIN; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HYDROGEN BONDING; MOLECULAR DYNAMICS SIMULATION; MUTATION, MISSENSE; PROLINE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84937734901     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.06.008     Document Type: Article

References (35)

1. Aherfi S., Solas C., Motte A., Moreau J., Borentain P., Mokhtari S., Botta-Fridlund D., Dhiver C., Portal I., Ruiz J.M. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France. J. Med. Virol. 2014, 86:1868-1876.
2. Bartenschlager R. The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J. Viral Hepat. 1999, 6:165-181.
3. Binkowski T.A., Naghibzadeh S., Liang J. CASTp: computed atlas of surface topography of proteins. Nucleic Acids Res. 2003, 31:3352-3355.
4. Boglione L., De Nicolò A., Cardellino C.S., Ruggiero T., Ghisetti V., Cariti G., Di Perri G., D'Avolio A. Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy. Clin. Microbiol. Infect. 2015, 21(2):205.e1-205.e3.
5. Cento V., Mirabelli C., Salpini R., Dimonte S., Artese A., Costa G., Mercurio F., Svicher V., Parrotta L., Bertoli A. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One 2012, 7:e39652.
6. Costantini S., Colonna G., Facchiano A.M. ESBRI: a web server for evaluating salt bridges in proteins. Bioinformation 2008, 3:137-138.
7. Dhanjal J.K., Goyal S., Sharma S., Hamid R., Grover A. Mechanistic insights into mode of action of potent natural antagonists of BACE-1 for checking Alzheimer's plaque pathology. Biochem. Biophys. Res. Commun. 2014, 443:1054-1059.
8. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., Shaw D.E., Francis P., Shenkin P.S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47:1739-1749.
9. Grover S., Dhanjal J.K., Goyal S., Grover A., Sundar D. Computational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus. BMC Bioinforma. 2014, 15:S13.
10. Guo Z., Prongay A., Tong X., Fischmann T., Bogen S., Velazquez F., Venkatraman S., Njoroge F.G., Madison V. Computational study of the effects of mutations A156T, D168V, and D168Q on the binding of HCV protease inhibitors. J. Chem. Theory Comput. 2006, 2:1657-1663.
11. Halfon P., Locarnini S. Hepatitis C virus resistance to protease inhibitors. J. Hepatol. 2011, 55:192-206.
12. Harper S., McCauley J.A., Rudd M.T., Ferrara M., DiFilippo M., Crescenzi B., Koch U., Petrocchi A., Holloway M.K., Butcher J.W., Romano J.J., Bush K.J., Gilbert K.F., McIntyre C.J., Nguyen K.T., Nizi E., Carroll S.S., Ludmerer S.W., Burlein C., DiMuzio J.M., Graham D.J., McHale C.M., Stahlhut M.W., Olsen D.B., Monteagudo E., Cianetti S., Giuliano C., Pucci V., Trainor N., Fandozzi C.M., Rowley M., Coleman P.J., Vacca J.P., Summa V., Liverton N.J. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med. Chem. Lett. 2012, 3:332-336.
13. Humphrey W., Dalke A., Schulten K. VMD: visual molecular dynamics. J. Mol. Graph. 1996, 14:33-38. (27-38).
14. Kairys V., Gilson M.K., Lather V., Schiffer C.A., Fernandes M.X. Toward the design of mutation-resistant enzyme inhibitors: further evaluation of the substrate envelope hypothesis. Chem. Biol. Drug Des. 2009, 74:234-245.
15. Kolykhalov A.A., Mihalik K., Feinstone S.M., Rice C.M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J. Virol. 2000, 74:2046-2051.
16. Laskowski R.A., Hutchinson E.G., Michie A.D., Wallace A.C., Jones M.L., Thornton J.M. PDBsum: a web-based database of summaries and analyses of all PDB structures. Trends Biochem. Sci. 1997, 22:488-490.
17. Lin T.I., Lenz O., Fanning G., Verbinnen T., Delouvroy F., Scholliers A., Vermeiren K., Rosenquist A., Edlund M., Samuelsson B., Vrang L., de Kock H., Wigerinck P., Raboisson P., Simmen K. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob. Agents Chemother. 2009, 53:1377-1385.
18. Liverton N.J., Carroll S.S., Dimuzio J., Fandozzi C., Graham D.J., Hazuda D., Holloway M.K., Ludmerer S.W., McCauley J.A., McIntyre C.J., Olsen D.B., Rudd M.T., Stahlhut M., Vacca J.P. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob. Agents Chemother. 2010, 54:305-311.
19. Lobanov M., Bogatyreva N.S., Galzitskaia O.V. Radius of gyration is indicator of compactness of protein structure. Mol. Biol. (Mosk) 2008, 42:701-706.
20. Patel K., Tyagi C., Goyal S., Dhanjal J.K., Bharadvaja N., Grover A. Curcumin-based IKKβ inhibiting anticancer lead design using novel fragment-based group QSAR modelling. Med. Chem. Res. 2014, 1-11.
21. Prongay A.J., Guo Z., Yao N., Pichardo J., Fischmann T., Strickland C., Myers J., Weber P.C., Beyer B.M., Ingram R., Hong Z., Prosise W.W., Ramanathan L., Taremi S.S., Yarosh-Tomaine T., Zhang R., Senior M., Yang R.S., Malcolm B., Arasappan A., Bennett F., Bogen S.L., Chen K., Jao E., Liu Y.T., Lovey R.G., Saksena A.K., Venkatraman S., Girijavallabhan V., Njoroge F.G., Madison V. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization. J. Med. Chem. 2007, 50:2310-2318.
22. Richard J.L., Barnard J.O., Zeuzem Stefan, John M. Analysis of resistance-associated amino acid variants (RAVs) in non-SVR patients enrolled in a retrospective long-term follow-up analysis of boceprevir phase 3 clinical studies. Hepatology 2011, 54:440A-441A.
23. Schrodinger L.L.C. The PyMOL Molecular Graphics System, Version 1.3r1 2010.
24. Seiwert S.D., Andrews S.W., Jiang Y., Serebryany V., Tan H., Kossen K., Rajagopalan P.T., Misialek S., Stevens S.K., Stoycheva A., Hong J., Lim S.R., Qin X., Rieger R., Condroski K.R., Zhang H., Do M.G., Lemieux C., Hingorani G.P., Hartley D.P., Josey J.A., Pan L., Beigelman L., Blatt L.M. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191. Antimicrob. Agents Chemother. 2008, 52:4432-4441.
25. Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., Halfon P., Inchauspe G., Kuiken C., Maertens G., Mizokami M., Murphy D.G., Okamoto H., Pawlotsky J.M., Penin F., Sablon E., Shin I.T., Stuyver L.J., Thiel H.J., Viazov S., Weiner A.J., Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42:962-973.
26. Susser S., Welsch C., Wang Y., Zettler M., Domingues F.S., Karey U., Hughes E., Ralston R., Tong X., Herrmann E., Zeuzem S., Sarrazin C. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009, 50:1709-1718.
27. Tong X., Chase R., Skelton A., Chen T., Wright-Minogue J., Malcolm B.A. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res. 2006, 70:28-38.
28. Tyagi C., Gupta A., Goyal S., Dhanjal J.K., Grover A. Fragment based group QSAR and molecular dynamics mechanistic studies on arylthioindole derivatives targeting the α-β interfacial site of human tubulin. BMC Genomics 2014, 15:S3.
29. Vats C., Dhanjal J.K., Goyal S., Bharadvaja N., Grover A. Computational design of novel flavonoid analogues as potential AChE inhibitors: analysis using group-based QSAR, molecular docking and molecular dynamics simulations. Struct. Chem. 2014, 1-10.
30. Vats C., Dhanjal J.K., Goyal S., Gupta A., Bharadvaja N., Grover A. Mechanistic analysis elucidating the relationship between Lys96 mutation in Mycobacterium tuberculosis pyrazinamidase enzyme and pyrazinamide susceptibility. BMC Genomics 2015, 16:S14.
31. Victrelis (boceprevir), 2011.
32. Vriend G. WHAT IF: a molecular modeling and drug design program. J. Mol. Graph. 1990, 8:52-56. (29).
33. Welsch C., Domingues F.S., Susser S., Antes I., Hartmann C., Mayr G., Schlicker A., Sarrazin C., Albrecht M., Zeuzem S., Lengauer T. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biol. 2008, 9:R16.
34. Welsch C., Schweizer S., Shimakami T., Domingues F.S., Kim S., Lemon S.M., Antes I. Ketoamide resistance and hepatitis C virus fitness in val55 variants of the NS3 serine protease. Antimicrob. Agents Chemother. 2012, 56:1907-1915.
35. World Health Organization Hepatitis C fact sheet. Hepatology 2014, (http://www.who.int/mediacentre/factsheets/fs164/en/).